OSE Immunotherapeutics SA announced that the Japanese Patent Office has issued the notice of allowance for a new patent family related to Tedopi®, a combination of neoepitopes, for use in the treatment of brain metastasis originating from cancers, including non-small cell lung cancer (NSCLC), in HLA-A2 positive patients. This patent provides a protection covering the use of Tedopi® in the treatment of brain metastasis until 2034. Brain metastasis is associated with poor prognosis as well as significant morbidity, creating a large unmet medical need. The new Tedopi® patent originated from Phase 2 results conducted in NSCLC patients. In the study, patients with brain metastasis showed longer than expected overall survival as well as longer time without disease progression, considering the advanced stage and the poor prognosis of these brain metastasis patients heavily previously treated.